Boehringer partners with Bactevo on drug discovery

Boehringer Ingelheim collaborates with UK tech enabled research firm Bactevo.
Aiming to identify small molecule lead compounds, the collaboration will see Bactevo use its Totally Integrated Medicines Engine Platform (TIME) as wells as its chemistry technology to enhance speed, efficiency and quality when detecting novel enabled leads.
Upfront payments will be sent to Bactevo from Boehringer to aid funding for research development and commercialisation.
David Williams, chief executive officer of Bactevo, said: “We are pleased to be commencing this highly complementary collaboration with Boehringer Ingelheim. It combines our cutting-edge TIME drug discovery platform with the powerful therapeutic drug development and commercialisation experience at Boehringer Ingelheim to create much needed new medicines in areas outside of our current therapeutic focus.”